MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 7851-7860 Newer>
The Motley Fool
September 2, 2011
Brian D. Pacampara
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. mark for My Articles 69 similar articles
The Motley Fool
September 2, 2011
David Williamson
When a Good Idea Goes Bad And with it go AstraZeneca's hopes of differentiation in a generic world. mark for My Articles 341 similar articles
The Motley Fool
September 2, 2011
Brian Orelli
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. mark for My Articles 433 similar articles
The Motley Fool
September 2, 2011
Becca Lipman
Investing 101: Rallying Health Care Stocks Being Snapped Up by the Smart Money Do you think these rallying health care stocks will continue to trade higher?: Pharmacyclics... Akorn... Endologix... Continucare... Jazz Pharmaceuticals... Seattle Genetics... Heartware International... Cubist Pharmaceuticals... Medicis Pharmaceutical... Watson... mark for My Articles 164 similar articles
The Motley Fool
September 2, 2011
Frank Vinluan
Pfizer Extends Icagen Offer; Remains Just Shy of Shares Needed for Deal There's a deadline. mark for My Articles 159 similar articles
The Motley Fool
September 1, 2011
Dan Radovsky
Who Will Build Your Replacement Kidney? Medical technology firms eye the future for grow-your-own body parts. mark for My Articles 43 similar articles
Chemistry World
September 2011
Column: In the pipeline Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal mark for My Articles 307 similar articles
The Motley Fool
August 31, 2011
Brian Orelli
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. mark for My Articles 109 similar articles
The Motley Fool
August 31, 2011
Brian Orelli
Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by. mark for My Articles 116 similar articles
The Motley Fool
August 31, 2011
Brian Orelli
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... mark for My Articles 475 similar articles
<Older 7851-7860 Newer>    Return to current articles.